CytoSorbents Corporation announced its participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on September 9-10 in New York City. CEO Dr. Phillip Chan and CFO Peter Mariani will present to investors and hold meetings, highlighting the company's blood purification technologies used in critical care and cardiac surgery. This event offers CytoSorbents a platform to engage with investors and discuss regulatory progress and product developments, including their DrugSorb®-ATR system seeking FDA approval. The conference gathers key players in biotech and healthcare, providing networking and growth opportunities for CytoSorbents.
United Natural Foods (UNFI) is set to report Q4 earnings with revenue expected around $7.71 billion, a slight 1.6% decline from last year due to network optimization. Despite the revenue drop, EPS is forecasted to rise sharply to $0.61-$0.62, a signi...
Oracle reported strong fiscal 2026 results with 17% revenue growth to $67 billion and a 36% net income increase, driven by a 75% surge in its cloud infrastructure segment. Despite a recent 55% stock price drop from its peak, Morgan Stanley raised Ora...
RBC Capital increased its price target for cybersecurity firm Zscaler to $210, maintaining an "Outperform" rating due to the company's strong financial results and AI innovation. Zscaler reported a 25% rise in revenue and Annual Recurring Revenue, su...
Lululemon Athletica's shares fell about 18% after the company lowered its full-year financial forecast for the second time, reflecting ongoing challenges. In Q2 2026, total net revenue dropped 4% to $2.40 billion, with a 10% fall in comparable sales ...
Teva Pharmaceutical Industries received a boost as UBS reaffirmed its "Buy" rating and raised the price target to $48, up from $36.62. This follows positive Phase 2a clinical trial results for TEV '408, a drug showing significant prevention of intest...
